News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
29 Results
Type
Company Profile (1)
Press Release (28)
Section
Business (6)
Deals (1)
FDA (5)
News (13)
Policy (2)
Tag
Alliances (3)
Approvals (5)
Biotechnology (1)
Europe (4)
Events (11)
FDA (5)
Hotbed/Location (24)
Massachusetts (1)
Mergers & acquisitions (1)
People (1)
Real estate (2)
Regulatory (2)
United States (1)
Date
Last 365 days (1)
2024 (1)
2021 (2)
2020 (2)
2019 (4)
2018 (5)
2017 (12)
2016 (2)
2012 (1)
29 Results for "ipsenus".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ipsen Biopharmaceuticals, Inc.
We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
June 27, 2024
Business
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately.
November 3, 2021
·
6 min read
Business
Ipsen Celebrates Opening of New Cambridge Headquarters with Day of Service
Ipsen officially opens North American headquarters at One Main Street and recently renovated R&D and Global External Innovation and Partnering facilities at 650 East Kendall Street
June 20, 2019
·
4 min read
Health Canada Approves INCRELEX First and Only Recombinant Human Insulin-like Growth Factor-1 (IGF-1) Therapy in Canada for the Treatment of Severe Growth Failure Associated with Ultra-Rare Condition in Children and Adolescents
Ipsen Biopharmaceuticals Canada Inc. today announced the commercial availability of INCRELEX® (mecasermin) for the treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (SPIGFD), following its Health Canada approval in December 2020.
March 16, 2021
·
10 min read
Policy
Ipsen Joins National Pharmaceutical Council
March 28, 2017
·
2 min read
Business
Ipsen Joins PhRMA To Continue Advancing Research And Innovation
October 12, 2017
·
4 min read
Business
Ipsen Release: Blazing New Trails: Updates In The Care Of Children With Cerebral Palsy
March 21, 2017
·
3 min read
FDA
Ipsen Announces Updated Indication for Dysport® (abobotulinumtoxinA) for the Treatment of Spasticity in Children
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), announced today that the United States Food and Drug Administration (FDA) has approved the expanded use of Dysport® (abobotulinumtoxinA) in pediatric patients
July 9, 2020
·
14 min read
Genetown
Multi-National PRESTO Study Presented by ENETS with Simultaneous Publication in Advances in Therapy
Ipsen Biopharmaceuticals, an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of the Presto study by ENETS.
March 11, 2020
·
15 min read
Business
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts
Today, Ipsen (Euronext: IPN; ADR: IPSEY), announced it will establish its North American headquarters in Cambridge, Massachusetts.
June 7, 2018
·
9 min read
1 of 3
Next